Compare Stocks

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$26.32 -4.8%	$35.42	$17.52 ▼ $43.81	$708.53M	2.6	457,498 shs	607,514 shs
CMPS COMPASS Pathways	$8.42 -1.3%	$9.98	$5.01 ▼ $12.75	$521.54M	2.48	694,219 shs	291,553 shs
KROS Keros Therapeutics	$58.95 -0.5%	$63.72	$27.02 ▼ $73.00	$2.12B	1.26	420,517 shs	296,468 shs
TRIL Trillium Therapeutics	$18.44	$18.12	$5.80 ▼ $20.96	$1.94B	2.08	1.87 million shs	8 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-4.78%	-19.11%	-22.04%	-19.68%	-5.90%
CMPS COMPASS Pathways	-1.29%	-8.28%	-11.65%	+4.86%	-13.91%
KROS Keros Therapeutics	-0.54%	-4.77%	-8.18%	+11.33%	+37.09%
TRIL Trillium Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	1.8423 of 5 stars	3.5	0.0	0.0	0.0	2.6	3.3	0.6
CMPS COMPASS Pathways	2.0295 of 5 stars	3.5	2.0	0.0	0.0	2.4	3.3	0.0
KROS Keros Therapeutics	2.9157 of 5 stars	4.5	1.0	0.0	0.0	3.1	3.3	0.0
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.00	Buy	$61.33	133.03% Upside
CMPS COMPASS Pathways	3.00	Buy	$47.40	462.95% Upside
KROS Keros Therapeutics	3.00	Buy	$86.00	45.89% Upside
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest TRIL, KROS, ARCT, and CMPS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/18/2024	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
4/1/2024	CMPS COMPASS Pathways	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$30.00
3/27/2024	KROS Keros Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00
3/20/2024	ARCT Arcturus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
3/13/2024	KROS Keros Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
3/8/2024	ARCT Arcturus Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/1/2024	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$120.00
3/1/2024	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
2/29/2024	KROS Keros Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$86.00
2/21/2024	KROS Keros Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/8/2024	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $48.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$169.93M	4.17	N/A	N/A	$10.42 per share	2.53
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$3.65 per share	N/A
KROS Keros Therapeutics	$150K	14,140.14	N/A	N/A	$11.09 per share	5.32
TRIL Trillium Therapeutics	$150K	12,907.39	N/A	N/A	$2.56 per share	7.20

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$29.73M	-$1.04	N/A	5.16	N/A	-15.65%	-18.22%	-11.95%	5/14/2024 (Estimated)
CMPS COMPASS Pathways	-$118.46M	-$2.39	N/A	N/A	N/A	N/A	-58.72%	-49.46%	5/9/2024 (Estimated)
KROS Keros Therapeutics	-$152.99M	-$5.20	N/A	N/A	N/A	N/A	-46.74%	-42.59%	5/2/2024 (Estimated)
TRIL Trillium Therapeutics	-$59.35M	$0.62	29.74	N/A	N/A	N/A	-23.31%	-18.66%	N/A

Latest TRIL, KROS, ARCT, and CMPS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/7/2024	Q4 2023	ARCT Arcturus Therapeutics	-$1.69	-$0.32	+$1.37	-$0.32	$64.14 million	$33.99 million
3/1/2024	Q4 2023	KROS Keros Therapeutics	-$1.37	-$1.34	+$0.03	-$1.34	N/A	$0.14 million
2/29/2024	Q4 2023	CMPS COMPASS Pathways	-$0.37	-$0.53	-$0.16	-$0.53	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	4.72	4.72
CMPS COMPASS Pathways	0.14	13.33	13.33
KROS Keros Therapeutics	N/A	14.25	14.25
TRIL Trillium Therapeutics	N/A	19.82	19.82

Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
CMPS COMPASS Pathways	46.19%
KROS Keros Therapeutics	71.56%
TRIL Trillium Therapeutics	87.15%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	13.80%
CMPS COMPASS Pathways	23.99%
KROS Keros Therapeutics	28.00%
TRIL Trillium Therapeutics	9.10%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	26.92 million	23.20 million	Optionable
CMPS COMPASS Pathways	186	61.94 million	47.08 million	Optionable
KROS Keros Therapeutics	136	35.98 million	25.91 million	Optionable
TRIL Trillium Therapeutics	33	105.00 million	95.44 million	Optionable

TRIL, KROS, ARCT, and CMPS Headlines

Source	Headline
	Cachet Bicycle shakes off COVID baytoday.ca - February 25 at 12:23 PM
	Rejuvenate your look with a trip to Fourth Avenue Medical Aesthetics chch.com - January 30 at 5:32 PM
	TTI apprehends motorists for illegal removal of clamps, hunt for four others underway bulawayo24.com - January 30 at 5:32 PM
	BridgeBio raises $1.25bn, and other biotech financings pharmaphorum.com - January 19 at 7:18 AM
	Ratio Therapeutics Raises $50M in Series B Financing precisionmedicineonline.com - January 17 at 1:39 PM
	Leiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.com businesswire.com - November 10 at 1:22 PM
	Mirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, Predictions benzinga.com - November 8 at 1:30 AM
	The Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast period uk.finance.yahoo.com - July 31 at 9:03 AM
	Ratio Therapeutics unveils new research and development facility biopharma-reporter.com - May 15 at 10:33 AM
	WHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death' msn.com - April 26 at 12:18 AM
	Leukemia Therapeutics Global Market Report 2023 uk.finance.yahoo.com - April 4 at 10:35 AM
	Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck finance.yahoo.com - March 28 at 9:12 AM
	Trillium House, an affordable housing project in Warrenton, close to completion dailyastorian.com - January 10 at 12:26 AM
	FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma nz.finance.yahoo.com - October 19 at 9:39 AM
	Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment seekingalpha.com - September 14 at 9:48 AM
	Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors nz.finance.yahoo.com - September 12 at 7:55 AM
	Pfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is Needed seekingalpha.com - August 17 at 11:07 AM
	TTI reviews parking model chronicle.co.zw - August 10 at 10:41 PM
	TTI working round the clock to configure its systems chronicle.co.zw - August 10 at 10:41 PM
	Pfizer in advanced talks to buy firm making sickle cell drugs pmnewsnigeria.com - August 7 at 3:57 AM
	10 Psychedelics CEOs To Pay Attention To In 2022 markets.businessinsider.com - June 22 at 10:08 AM
	Highlights from ASCO Annual Meeting 2022 healio.com - June 15 at 1:37 PM
	Chlormethine gel may be more effective than ointment for mycosis fungoides healio.com - May 27 at 4:34 PM
	Pfizer and Moderna created life-saving vaccines. So why are their stocks crumbling? edition.cnn.com - May 20 at 2:06 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Arcturus Therapeutics

NASDAQ:ARCT

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

COMPASS Pathways

NASDAQ:CMPS

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Keros Therapeutics

NASDAQ:KROS

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Trillium Therapeutics

NASDAQ:TRIL

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial